Litfulo Capsules Special Investigation

Pfizer

Status: Active, not recruiting

Conditions: Alopecia Areata

Treatments: Drug: LITFULO

Study type: Observational

Funder types: Industry

Identifiers

NCT06279221

B7981055

NCT06279221 (Registry Identifier)

Details and patient eligibility

About

The objective of this Study is to confirm the safety during the long-term use of this drug and the effectiveness during the use of this drug under the actual use in the patients treated with this drug.

Full description

This study is an open-label, multi-center, one arm prospective observational cohort study of patients receiving this drug. The investigators complete the CRF based on the information extracted from the medical record created in daily medical practice.

Enrollment: 191 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

• Patients with alopecia areata who start receiving this drug for the first time after the contract date of this study
• Patients who have not participated in a clinical trial (clinical study) of this drug

Exclusion criteria

Patients meeting any of the following criteria will not be included in the study:

• Patients previously enrolled in this study
• Patients with a history of treatment with this drug (including investigational product)

Trial design

191 participants in 1 patient group

Japanese participants with alopecia areata

Description:

Japanese participants with alopecia areata

Treatment:

Drug: LITFULO